Global Brain has invested in Rege Nephro Co., Ltd., a clinical-stage drug discovery company focused on kidney diseases

Global Brain has invested in Rege Nephro Co., Ltd. (Rege Nephro), a clinical-stage drug discovery company focused on kidney diseases, through its 321FORCE Global Innovation Fund L.P. (321FORCE™).

Rege Nephro is a clinical-stage drug discovery startup leveraging technology based on the research seeds of Professor Kenji Osafune of Center for iPS Cell Research and Application, Kyoto University. The company has identified RN-014, a retinoic acid receptor (RAR) agonist, as a candidate drug for the treatment of autosomal dominant polycystic kidney disease (ADPKD), which is expected to suppress cyst formation and improve kidney function. Rege Nephro began its Phase 2a clinical trials in December 2023. Additionally, through multiple mouse model experiments, they discovered that iPS cell-derived nephron progenitor cells (iNPC) under the renal capsule improved deteriorated kidney function. They are advancing the development of cell therapy for chronic kidney disease (CKD) using iNPC (RN-032).

Global Brain has decided to invest in Rege Nephro, based on its high regard for Rege Nephro’s business and talented management team with the ability to bring its plans to fruition. Global Brain will contribute to the growth of Rege Nephro’s business in collaboration with Mitsui Chemicals, Inc.